Fulvio Mavilio

Fulvio Mavilio is currently a Member at the European Molecular Biology Organization, a Professor of Molecular Biology at Università degli Studi di Modena e Reggio Emilia, Senior Vice President of Translational Science at Astellas Gene Therapies, Inc. since 2019, and Chief Scientific Officer at Orchard Therapeutics Plc since 2022.
Former positions include Discovery Director at AGC Biologics SpA from 2002 to 2005, Director of the Centre for Regenerative Medicine at Università degli Studi di Modena e Reggio Emilia from 2006 to 2011, Director at San Raffaele-Telethon Institute for Gene Therapy from 1995 to 2002, Director at the American Society of Gene & Cell Therapy, Chief Scientific Officer at Genethon from 2012 to 2017, and Chief Scientific Officer at Smart Immune SAS. Education includes an undergraduate degree earned in 1976 and a doctorate earned in 1979, both from Università degli Studi di Roma Tor Vergata.